Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Apremilast

FDA-approved product (tablet, oral), marketed as Apremilast, Otezla, Otezla Xr.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Apremilast
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Behcet's syndrome
  • Immune system disease
  • Oral ulcer
  • Psoriasis
  • Psoriasis vulgaris
  • Psoriatic arthritis
  • Pustulosis palmaris et plantaris

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective immunosuppressants
FDA pharmacologic class
Phosphodiesterase 4 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli35.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Apremilast in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Apremilast with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Spanish Registry of Systemic Treatments in Psoriasis

    NCT02075697 · start 2008-10

    Registered record
    Registry ID
    NCT02075697
    Conditions
    Psoriasis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2008-10
    Completion
    2025-10
    Enrolment
    3,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Safety and Efficacy of CC-10004 for Prurigo Nodularis

    NCT00869089 · start 2008-09

    Registered record
    Registry ID
    NCT00869089
    Conditions
    Prurigo Nodularis
    Interventions
    CC-10004
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-09
    Completion
    2011-01
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrurigo Nodularis
    InterventionCC-10004
    PhasePhase 2
    Registry statusCompleted

  • An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

    NCT00701311 · start 2008-06

    Registered record
    Registry ID
    NCT00701311
    Conditions
    Prostatitis; Chronic Prostatitis With Chronic Pelvic Pain Syndrome
    Interventions
    CC-10004
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-06
    Completion
    2011-03
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatitis; Chronic Prostatitis With Chronic Pelvic Pain Syndrome
    InterventionCC-10004
    PhasePhase 2
    Registry statusCompleted

  • Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

    NCT00708916 · start 2008-06

    Registered record
    Registry ID
    NCT00708916
    Conditions
    Discoid Lupus Erythematosus
    Interventions
    CC-10004
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2008-06
    Completion
    2010-08
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiscoid Lupus Erythematosus
    InterventionCC-10004
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • PsoBest - The German Psoriasis Registry

    NCT01848028 · start 2008-01

    Registered record
    Registry ID
    NCT01848028
    Conditions
    Psoriasis; Psoriatic-arthritis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2008-01
    Completion
    2032-12
    Enrolment
    3,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Psoriatic-arthritis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting